And more to come and we expect to continue to execute and deliver on key catalysts which include, treating the first patients in our new INFINITY Phase II trial and DME in the coming weeks; presenting OPTIC [Phonetic] data for all four cohorts by the end of this year; and then, advancing our preclinical gene therapies to broaden our pipeline opportunities, so stay tuned.Thank you.
And I think that should be our base case. They go primarily on the OCT. Thanks for the additional thoughts, fascinating trial design.So we've seen that there was stable protein expression but looking at the inflammation, specifically, we see a peak early on and it's in that range for around four to six weeks, which corresponds with kind of peak transduction and thereafter we see a decline. Sure. We have been preparing for this and our INFINITY Phase II trial is open for patient enrollment, as Aaron will describe in more detail.But Aaron, do you want to go through a couple of things we've been thinking about? You mentioned registration endpoints as well.
[Operator Instructions] Your first question comes from the line of Tyler Van Buren with Piper Sandler.I am on mute. Thanks.The key takeaways from this presentation of OPTIC data through April 1st, 2020 were as follows; long-term durability beyond one year from a single intravitreal injection has been demonstrated with zero rescue injections in Cohort 1 out to a median of 60 weeks follow-up, we saw further evidence of a dose response at 6E11 and 2E11 dose levels across all three cohorts, evidence from Cohort 3 was presented indicating that the prophylactic regimen of topical steroids is effective at minimizing early ocular inflammation, early data in the first five patients with 20 weeks follow-up in Cohort 3 show improvements in visual acuity and reductions in macular thickness as assessed by OCT.So I think what we've seen in Cohorts 1 and 2 is we haven't seen any new clinically relevant inflammation episode at the later time points, which again fits with the nonhuman primate data. So indicates that most of the inflammation is happening early and the active inflammation is not something that continues. Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC … We prefer to do that rather than sometimes, than to take patients off too early. These are effective, but typically require frequent and long-term injections for patients to maintain good vision.Good afternoon, and welcome to the Adverum Biotechnologies' First Quarter 2020 Corporate Update Conference Call.
This information will only be used for this request. Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME) Jul 06 2020.
Get short term trading ideas from the MarketBeat Idea Engine. There's significant unmet needs.
Get prepared with the key expectations. But these are very stringent and they are right at the most stringent end of criteria that have been used in DME trials and that's really because they then support our hypothesis and our assumptions that we would expect to have more than 50% of the aflibercept patients treated by that time point. I mean what percentage of aflibercept patients can go 24 weeks DME -- aflibercept patients can go 24 weeks without an injection?Yes for sure. It's a randomized trial.
I'm talking about center-involving DME. And as we follow-up the patients for longer, is that those markers of inflammation are coming down. Luca Issi from RBC Capital. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.
And I think to your point around COVID, there is still to be played out here in terms of the overall impact over the longer haul.Hi, hello.
Want to see which stocks are moving?
Since 1988 it has more than doubled the S&P 500 with an average gain of +24.33% per year.
Find the latest Earnings Report Date for Adverum Biotechnologies, Inc. Common Stock (ADVM) at Nasdaq.com. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04).
Today we issued a press release announcing our new INFINITY trial for ADVM-022 in Diabetic Macular Edema, as well as reporting our financial results for the first quarter of 2020. So the steroid eye drops are controlling it well.Thank you.